线祖利德在体外对抗异常病原体的抗菌活性
Ting Wang1, Huiyue Zhang1, Rui Feng1
1Shandong Second Provincial General Hospital, Jinan, China.
PeerJ
|February 17, 2025
概括
线索利德是一种oxazolidinone抗生素,在体外表现出对Mycobacterium tuberculosis,Nocardia和Corynebacterium的强烈活性. 它还表现出对非结核性菌根菌和厌氧生物的作用,扩大了其潜在的治疗应用.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 利尼佐利德主要被批准用于治疗格拉姆阳性细菌感染.
- 新出现的证据表明,linezolid对更广泛的微生物具有活性.
- 这包括mycobacteria,Nocardia,Corynebacterium,厌氧生物和真菌.
研究的目的:
- 审查linezolid对其批准频谱之外的病原体的体外抗菌和抗真菌活性.
- 编制和分析这些非标签目标的最小抑制度 (MIC) 数据.
- 评估扩大临床使用和新药开发的潜力.
主要方法:
- 文献综述侧重于对linezolid的体外研究.
- 汇编报告的MIC范围,MIC50和MIC90值.
- 分析了linezolid对Mycobacterium tuberculosis,NTM,Nocardia,Corynebacterium,厌氧生物和Candida物种的活性.
主要成果:
- 莱涅佐利德显示强烈的抑制 (MIC ≤2μg/mL) 对抗M.结核病,诺卡迪亚和Corynebacterium.
- 观察到对非结核性菌根菌的中度至强烈活性 (MIC 0.06-128 μg/mL).
- 对于无气体动物 (MIC 0.003-16 μg/mL) 发现了物种依赖性影响,并且报告了对Candida的协同抗真菌增强.
结论:
- 莱涅佐利德在体外表现出显著的活性,除了其主要指示之外,它对各种病原体具有显著的活性.
- 这些发现支持扩大linezolid的临床应用,并为新药发现提供了基础.
- 需要进一步的研究来将这些体外发现转化为临床实践.
更多相关视频
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
6.8K
06:18A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
1.3K
相关概念视频
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...